Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
11/13/24 Curium Pharma Lu-177-PSMA-I&T for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
11/11/24 AbbVie (ABBV) Emraclidine for Schizophrenia Subscribers Only Subscribers Only Subscribers Only
11/8/24 Paratek Nuzyra for Non-Tuberculous Mycobacteria (NTM) Subscribers Only Subscribers Only Subscribers Only
11/1/24 Novo Nordisk (NVO) Semaglutide (NASH) for Non-Alcoholic Steatohepatitis (NASH) Subscribers Only Subscribers Only Subscribers Only
10/31/24 Lexicon Pharmaceuticals (LXRX) Inpefa for Diabetes Mellitus, Type I Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
09/12/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/16/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/24/2024 Subscribers Only Subscribers Only Trial Data - Top-Line Results
10/26/2024 Subscribers Only Subscribers Only Trial Data - Updated Results
10/30/2024 Subscribers Only Subscribers Only Progress Update - Development Review